Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

Drug development against human adenoviruses and its advancement by Syrian hamster models.

Wold WS, Tollefson AE, Ying B, Spencer JF, Toth K.

FEMS Microbiol Rev. 2019 Mar 27. pii: fuz008. doi: 10.1093/femsre/fuz008. [Epub ahead of print]

PMID:
30916746
2.

The Virology of Taterapox Virus In Vitro.

Parker S, Camilo de Oliveira L, Lefkowitz EJ, Hendrickson RC, Bonjardim CA, Wold WSM, Hartzler H, Crump R, Buller RM.

Viruses. 2018 Aug 29;10(9). pii: E463. doi: 10.3390/v10090463.

3.

Characterization of an N-Terminal Non-Core Domain of RAG1 Gene Disrupted Syrian Hamster Model Generated by CRISPR Cas9.

Miao J, Ying B, Li R, Tollefson AE, Spencer JF, Wold WSM, Song SH, Kong IK, Toth K, Wang Y, Wang Z.

Viruses. 2018 May 6;10(5). pii: E243. doi: 10.3390/v10050243.

4.

USC-087 protects Syrian hamsters against lethal challenge with human species C adenoviruses.

Toth K, Spencer JF, Ying B, Tollefson AE, Hartline CB, Richard ET, Fan J, Lyu J, Kashemirov BA, Harteg C, Reyna D, Lipka E, Prichard MN, McKenna CE, Wold WSM.

Antiviral Res. 2018 May;153:1-9. doi: 10.1016/j.antiviral.2018.03.001. Epub 2018 Mar 3.

5.

Maurice Green - A pioneering virologist.

Loewenstein PM, Green ED, Wold WSM.

Virology. 2018 Feb;515:261-262. doi: 10.1016/j.virol.2017.12.030. Epub 2018 Jan 9. No abstract available.

6.

Male Syrian hamsters are more susceptible to intravenous infection with species C human adenoviruses than are females.

Ying B, Spencer JF, Tollefson AE, Wold WSM, Toth K.

Virology. 2018 Jan 15;514:66-78. doi: 10.1016/j.virol.2017.10.015. Epub 2017 Nov 10.

7.

Anti-adenoviral Artificial MicroRNAs Expressed from AAV9 Vectors Inhibit Human Adenovirus Infection in Immunosuppressed Syrian Hamsters.

Schaar K, Geisler A, Kraus M, Pinkert S, Pryshliak M, Spencer JF, Tollefson AE, Ying B, Kurreck J, Wold WS, Klopfleisch R, Toth K, Fechner H.

Mol Ther Nucleic Acids. 2017 Sep 15;8:300-316. doi: 10.1016/j.omtn.2017.07.002. Epub 2017 Jul 8.

8.

Combination therapy with brincidofovir and valganciclovir against species C adenovirus infection in the immunosuppressed Syrian hamster model allows for substantial reduction of dose for both compounds.

Toth K, Tollefson AE, Spencer JF, Ying B, Wold WSM.

Antiviral Res. 2017 Oct;146:121-129. doi: 10.1016/j.antiviral.2017.08.002. Epub 2017 Aug 4.

PMID:
28827083
9.

HAdV-C6 Is a More Relevant Challenge Virus than HAdV-C5 for Testing Antiviral Drugs with the Immunosuppressed Syrian Hamster Model.

Toth K, Spencer JF, Ying B, Tollefson AE, Wold WSM.

Viruses. 2017 Jun 13;9(6). pii: E147. doi: 10.3390/v9060147.

10.

Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5.

Tollefson AE, Ying B, Spencer JF, Sagartz JE, Wold WSM, Toth K.

J Virol. 2017 Apr 28;91(10). pii: e00284-17. doi: 10.1128/JVI.00284-17. Print 2017 May 15.

11.

Correction: STAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon Response in Viral Control.

Toth K, Lee SR, Ying B, Spencer JF, Tollefson AE, Sagartz JE, Kong IK, Wang Z, Wold WS.

PLoS Pathog. 2016 Jan 8;12(1):e1005392. doi: 10.1371/journal.ppat.1005392. eCollection 2016 Jan.

12.

Tristetraprolin induces cell cycle arrest in breast tumor cells through targeting AP-1/c-Jun and NF-κB pathway.

Xu L, Ning H, Gu L, Wang Q, Lu W, Peng H, Cui W, Ying B, Ross CR, Wilson GM, Wei L, Wold WS, Liu J.

Oncotarget. 2015 Dec 8;6(39):41679-91. doi: 10.18632/oncotarget.6149.

13.

New drug on the horizon for treating adenovirus.

Wold WS, Toth K.

Expert Opin Pharmacother. 2015;16(14):2095-9. doi: 10.1517/14656566.2015.1083975. Epub 2015 Sep 2.

14.

Transcriptome sequencing and development of an expression microarray platform for liver infection in adenovirus type 5-infected Syrian golden hamsters.

Ying B, Toth K, Spencer JF, Aurora R, Wold WS.

Virology. 2015 Nov;485:305-12. doi: 10.1016/j.virol.2015.07.024. Epub 2015 Aug 28.

15.

STAT2 Knockout Syrian Hamsters Support Enhanced Replication and Pathogenicity of Human Adenovirus, Revealing an Important Role of Type I Interferon Response in Viral Control.

Toth K, Lee SR, Ying B, Spencer JF, Tollefson AE, Sagartz JE, Kong IK, Wang Z, Wold WS.

PLoS Pathog. 2015 Aug 20;11(8):e1005084. doi: 10.1371/journal.ppat.1005084. eCollection 2015 Aug. Erratum in: PLoS Pathog. 2016 Jan;12(1):e1005392.

16.

Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male Syrian hamsters.

Toth K, Ying B, Tollefson AE, Spencer JF, Balakrishnan L, Sagartz JE, Buller RM, Wold WS.

Viruses. 2015 Mar 23;7(3):1409-28. doi: 10.3390/v7031409.

17.

Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model.

Tollefson AE, Spencer JF, Ying B, Buller RM, Wold WS, Toth K.

Antiviral Res. 2014 Dec;112:38-46. doi: 10.1016/j.antiviral.2014.10.005. Epub 2014 Oct 15.

PMID:
25453340
18.

Inhibitors of nucleotidyltransferase superfamily enzymes suppress herpes simplex virus replication.

Tavis JE, Wang H, Tollefson AE, Ying B, Korom M, Cheng X, Cao F, Davis KL, Wold WS, Morrison LA.

Antimicrob Agents Chemother. 2014 Dec;58(12):7451-61. doi: 10.1128/AAC.03875-14. Epub 2014 Sep 29.

19.

Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters.

Ying B, Tollefson AE, Spencer JF, Balakrishnan L, Dewhurst S, Capella C, Buller RM, Toth K, Wold WS.

Antimicrob Agents Chemother. 2014 Dec;58(12):7171-81. doi: 10.1128/AAC.03860-14. Epub 2014 Sep 15.

20.
21.

Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.

Wold WS, Toth K.

Curr Gene Ther. 2013 Dec;13(6):421-33. Review.

22.

Adenovirus death protein (ADP) is required for lytic infection of human lymphocytes.

Murali VK, Ornelles DA, Gooding LR, Wilms HT, Huang W, Tollefson AE, Wold WS, Garnett-Benson C.

J Virol. 2014 Jan;88(2):903-12. doi: 10.1128/JVI.01675-13. Epub 2013 Nov 6.

23.

The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors.

Young BA, Spencer JF, Ying B, Tollefson AE, Toth K, Wold WS.

Cancer Gene Ther. 2013 Sep;20(9):521-30. doi: 10.1038/cgt.2013.49. Epub 2013 Aug 9.

24.

The effects of radiation on antitumor efficacy of an oncolytic adenovirus vector in the Syrian hamster model.

Young BA, Spencer JF, Ying B, Toth K, Wold WS.

Cancer Gene Ther. 2013 Sep;20(9):531-7. doi: 10.1038/cgt.2013.50. Epub 2013 Aug 9.

25.

Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds.

Wold WS, Toth K.

Adv Cancer Res. 2012;115:69-92. doi: 10.1016/B978-0-12-398342-8.00003-3. Review.

PMID:
23021242
26.

Increasing the efficacy of oncolytic adenovirus vectors.

Toth K, Wold WS.

Viruses. 2010 Sep;2(9):1844-66. doi: 10.3390/v2091844. Epub 2010 Aug 27.

27.

Syrian hamster tumor model to study oncolytic Ad5-based vectors.

Dhar D, Toth K, Wold WS.

Methods Mol Biol. 2012;797:53-63. doi: 10.1007/978-1-61779-340-0_4.

PMID:
21948468
28.

Identification of a previously unrecognized promoter that drives expression of the UXP transcription unit in the human adenovirus type 5 genome.

Ying B, Tollefson AE, Wold WS.

J Virol. 2010 Nov;84(21):11470-8. doi: 10.1128/JVI.01338-10. Epub 2010 Aug 25.

29.

A fully replication-competent adenovirus vector with enhanced oncolytic properties.

Toth K, Kuppuswamy M, Shashkova EV, Spencer JF, Wold WS.

Cancer Gene Ther. 2010 Nov;17(11):761-70. doi: 10.1038/cgt.2010.33. Epub 2010 Jul 2.

30.

Oncolytic (replication-competent) adenoviruses as anticancer agents.

Toth K, Dhar D, Wold WS.

Expert Opin Biol Ther. 2010 Mar;10(3):353-68. doi: 10.1517/14712590903559822. Review.

PMID:
20132057
31.

Adenovirus E1A and E1B-19K proteins protect human hepatoma cells from transforming growth factor beta1-induced apoptosis.

Tarakanova VL, Wold WS.

Virus Res. 2010 Jan;147(1):67-76. doi: 10.1016/j.virusres.2009.10.008. Epub 2009 Oct 23.

32.

Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model.

Dhar D, Spencer JF, Toth K, Wold WS.

Mol Ther. 2009 Oct;17(10):1724-32. doi: 10.1038/mt.2009.156. Epub 2009 Jul 14.

33.

New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.

Spencer JF, Sagartz JE, Wold WS, Toth K.

Cancer Gene Ther. 2009 Dec;16(12):912-22. doi: 10.1038/cgt.2009.36. Epub 2009 May 29.

34.

An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector.

Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer JM, Shashkova EV, Kuppuswamy M, Dhar D, Thomas MA, Tollefson AE, Zumstein LA, Wold WS, Toth K.

Cancer Gene Ther. 2009 Aug;16(8):644-54. doi: 10.1038/cgt.2009.5. Epub 2009 Feb 6.

35.

INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies.

Ying B, Toth K, Spencer JF, Meyer J, Tollefson AE, Patra D, Dhar D, Shashkova EV, Kuppuswamy M, Doronin K, Thomas MA, Zumstein LA, Wold WS, Lichtenstein DL.

Cancer Gene Ther. 2009 Aug;16(8):625-37. doi: 10.1038/cgt.2009.6. Epub 2009 Feb 6.

36.

Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.

Dhar D, Spencer JF, Toth K, Wold WS.

J Virol. 2009 Mar;83(5):2130-9. doi: 10.1128/JVI.02127-08. Epub 2008 Dec 10.

37.

Neuroadapted yellow fever virus strain 17D: a charged locus in domain III of the E protein governs heparin binding activity and neuroinvasiveness in the SCID mouse model.

Nickells J, Cannella M, Droll DA, Liang Y, Wold WS, Chambers TJ.

J Virol. 2008 Dec;82(24):12510-9. doi: 10.1128/JVI.00458-08. Epub 2008 Oct 8.

38.

Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.

Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS.

Mol Ther. 2008 Oct;16(10):1665-73. doi: 10.1038/mt.2008.162. Epub 2008 Jul 29.

39.

Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model.

Toth K, Spencer JF, Dhar D, Sagartz JE, Buller RM, Painter GR, Wold WS.

Proc Natl Acad Sci U S A. 2008 May 20;105(20):7293-7. doi: 10.1073/pnas.0800200105. Epub 2008 May 19.

40.

West Nile 25A virus infection of B-cell-deficient ((micro)MT) mice: characterization of neuroinvasiveness and pseudoreversion of the viral envelope protein.

Chambers TJ, Droll DA, Walton AH, Schwartz J, Wold WS, Nickells J.

J Gen Virol. 2008 Mar;89(Pt 3):627-35. doi: 10.1099/vir.0.83297-0.

PMID:
18272752
41.

Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.

Shashkova EV, Kuppuswamy MN, Wold WS, Doronin K.

Cancer Gene Ther. 2008 Feb;15(2):61-72. Epub 2007 Nov 9.

42.

Identification of a new human adenovirus protein encoded by a novel late l-strand transcription unit.

Tollefson AE, Ying B, Doronin K, Sidor PD, Wold WS.

J Virol. 2007 Dec;81(23):12918-26. Epub 2007 Sep 19.

43.

JE Nakayama/JE SA14-14-2 virus structural region intertypic viruses: biological properties in the mouse model of neuroinvasive disease.

Chambers TJ, Droll DA, Jiang X, Wold WS, Nickells JA.

Virology. 2007 Sep 15;366(1):51-61. Epub 2007 May 22.

44.

Preparation and titration of CsCl-banded adenovirus stocks.

Tollefson AE, Kuppuswamy M, Shashkova EV, Doronin K, Wold WS.

Methods Mol Med. 2007;130:223-35.

PMID:
17401177
45.

A real-time PCR method to rapidly titer adenovirus stocks.

Thomas MA, Lichtenstein DL, Krajcsi P, Wold WS.

Methods Mol Med. 2007;130:185-92.

PMID:
17401173
46.

Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors.

Thomas MA, Spencer JF, Wold WS.

Methods Mol Med. 2007;130:169-83.

PMID:
17401172
47.
48.

Targeting Interferon-α Increases Antitumor Efficacy and Reduces Hepatotoxicity of E1A-mutated Spread-enhanced Oncolytic Adenovirus.

Shashkova EV, Spencer JF, Wold WS, Doronin K.

Mol Ther. 2007 Mar;15(3):598-607. doi: 10.1038/sj.mt.6300064. Epub 2016 Dec 8.

49.

Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.

Shashkova EV, Spencer JF, Wold WS, Doronin K.

Mol Ther. 2007 Mar;15(3):598-607. Epub 2006 Dec 26.

50.

Chimeric Japanese encephalitis virus/dengue 2 virus infectious clone: biological properties, immunogenicity and protection against dengue encephalitis in mice.

Chambers TJ, Jiang X, Droll DA, Liang Y, Wold WS, Nickells J.

J Gen Virol. 2006 Nov;87(Pt 11):3131-40.

PMID:
17030845

Supplemental Content

Support Center